- Home
- WWR vs PYPD Comparison
WWR vs PYPD Comparison
Compare WWR & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WWR
- PYPD
- Stock Information
- Founded
- WWR 1977
- PYPD 2008
- Country
- WWR United States
- PYPD Israel
- Employees
- WWR N/A
- PYPD N/A
- Industry
- WWR Metal Mining
- PYPD Medical/Dental Instruments
- Sector
- WWR Basic Materials
- PYPD Health Care
- Exchange
- WWR Nasdaq
- PYPD Nasdaq
- Market Cap
- WWR N/A
- PYPD 36.0M
- IPO Year
- WWR N/A
- PYPD 2020
- Fundamental
- Price
- WWR $0.59
- PYPD $3.40
- Analyst Decision
- WWR Strong Buy
- PYPD Strong Buy
- Analyst Count
- WWR 1
- PYPD 5
- Target Price
- WWR $2.00
- PYPD $11.40
- AVG Volume (30 Days)
- WWR 607.4K
- PYPD 214.9K
- Earning Date
- WWR 08-13-2025
- PYPD 08-13-2025
- Dividend Yield
- WWR N/A
- PYPD N/A
- EPS Growth
- WWR N/A
- PYPD N/A
- EPS
- WWR N/A
- PYPD N/A
- Revenue
- WWR N/A
- PYPD N/A
- Revenue This Year
- WWR N/A
- PYPD N/A
- Revenue Next Year
- WWR N/A
- PYPD N/A
- P/E Ratio
- WWR N/A
- PYPD N/A
- Revenue Growth
- WWR N/A
- PYPD N/A
- 52 Week Low
- WWR $0.45
- PYPD $2.30
- 52 Week High
- WWR $1.32
- PYPD $4.42
- Technical
- Relative Strength Index (RSI)
- WWR 58.04
- PYPD 51.00
- Support Level
- WWR $0.59
- PYPD $3.34
- Resistance Level
- WWR $0.63
- PYPD $3.53
- Average True Range (ATR)
- WWR 0.03
- PYPD 0.15
- MACD
- WWR -0.00
- PYPD -0.04
- Stochastic Oscillator
- WWR 50.00
- PYPD 14.68
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.